After Tough 2011 For Chinese Healthcare IPOs, Policy And Cost Relief Could Be On The Way
This article was originally published in PharmAsia News
Executive Summary
China's pharma IPOs didn't meet the hype in 2011. Government action may now ease speculation mania.
You may also be interested in...
Traditional Chinese Medicines Seen As Global Growth Opportunity
HONG KONG - Health authorities around the world are working to develop regulatory structures for traditional Chinese medicines
With Pfizer As Cornerstone Investor, Will Shanghai Pharmaceutical Be Largest Pharma IPO Ever?
SHANGHAI - Shanghai Pharmaceutical Holdings Co. Ltd is set for what could be the largest IPO by a pharmaceutical company ever, surpassing Ostuka Holding's $2.4 billion IPO from last year
Squeezed by Price Caps And Rising Costs, China's Nepstar Drugstore Chain Pushes Its Own Brands
Want to get beverages on a drug store run for aspirin in China? Not a problem in Nepstar stores, where China's largest retail pharmacy chain is increasingly becoming more of a convenience store than a traditional drug store. It is shifting its business model to focus on private label products to fend off a double squeeze: swelling rental and labor costs and ongoing governmental reform initiatives to impose price caps on drug retailers